In the ongoing, not yet successful, search for a disease-modifying osteoarthritis drug (DMOAD), one recent focus involves inhibition of the aggrecanase ADAMTS-5 (a disintegrin and metalloproteinase with thrombospondin motifs), identified as a key protease in pathological degradation of human aggrecan [[3], [4], [5]]. Here, ACAN is linked to osteoarthritis.